PROVIDER PROFILE · NPI 1932376514

Farhad Ardeshirpour-ZartoshtiM.D.

PRACTICEFARHAD ARDESH MD INCSee all providers at this practice →

Plastic and Reconstructive SurgeryBeverly Hills, CAI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

Unique beneficiaries

—

Total services

Distinct HCPCS

Medicare payment

$11K

Peer benchmark

Total Medicare services vs. 396 Plastic and Reconstructive Surgery providers in CA — below median (cohort median 171).

PRESCRIBING · PART D · 2024

Total Rx claims

Beneficiaries

—

Total drug cost

$986

Distinct drugs

Brand share

27.1%

Top prescribed drugs

Cefadroxil20 claims

Amoxicillin/Potassium Clav19 claims

Doxycycline Hyclate18 claims

Omeprazole13 claims

QUALITY · MIPS · 2024

No data available for this provider in 2024.

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

Total received

$14K

Payment records

By payment type

Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$12K

Travel and Lodging$1K

Food and Beverage$350

REFERRAL NETWORK

Where Farhad Ardeshirpour-Zartoshti's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 2 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
SEVENTH-DAY ADVENTISTS LOMA LINDA UNIVERSITY MEDICAL CENTER	38	147
Abel Torres Micrographic Dermatologic Surgery · Loma Linda, CA	15	25

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history